Antisense oligonucleotides
View Patent ↗Embodiments of the present invention are directed generally to antisense compounds and compositions for the treatment of muscular dystrophy, and in particular, Duchenne muscular dystrophy (DMD). In one embodiment, the invention is directed to antisense oligonucleotide molecules, pharmaceutical compositions and formulations comprising antisense oligonucleotide molecules, and methods of treating muscular dystrophy related diseases and disorders wherein the antisense oligonucleotide molecules comprises a base sequence selected from the group consisting of SEQ ID NO: 5-8, 10, 12, 14, 16, 24, 27, 28, 34, 35, 37, 40, 42, 44-46, 79, 97, 100, 101, and 116, and combinations thereof.
1. An antisense oligonucleotide molecule for treating DMD, the antisense oligonucleotide molecule consisting of a base sequence of
(SEQ ID NO: 28)
CCAATGCCATCCTGGAGTTCCT
and analogs and combinations thereof,
wherein the analogs have a base sequence that varies from any one of the foregoing base sequences by:
1) substitution of one or more T bases with U bases, or vice versa;
2) deletion or substitution of up to two bases;
3) addition of one base to one or both ends of the sequence; or
4) deletion of one base at one or more ends of the sequence; and
wherein the molecule can bind to a target site to cause exon skipping in an exon of the dystrophin gene.
2. The antisense oligonucleotide molecule according to claim 1 , wherein the exon of the dystrophin gene at which exon skipping is caused is exon 45.
3. The antisense oligonucleotide molecule according to claim 1 , wherein the antisense oligonucleotide molecule is conjugated to or complexed with a distinct chemical entity.
4. The antisense oligonucleotide molecule according to claim 1 , wherein the antisense oligonucleotide molecule is a phosphorodiamidate morpholino oligonucleotide (PMO).
5. The antisense oligonucleotide molecule according to claim 1 , wherein the antisense oligonucleotide molecule is an oligomer which is capable of binding to its complementary RNA sequence.
6. The antisense oligonucleotide molecule according to claim 1 , wherein the antisense oligonucleotide molecule includes a deletion of one to two nucleotide bases at either end thereof.
7. A pharmaceutical composition for treating DMD, the composition comprising an antisense oligonucleotide molecule according to claim 1 , and a pharmaceutically acceptable carrier, adjuvant or vehicle.
8. A pharmaceutical composition comprising an antisense oligonucleotide conjugated with a polymer to enhance the delivery of antisense oligonucleotide and antisense effect, wherein the antisense oligonucleotide is
(SEQ ID NO: 28)
CCAATGCCATCCTGGAGTTCCT
and analogs and combinations thereof,
wherein the analogs have a base sequence that varies from any one of the foregoing base sequences by:
1) substitution of one or more T bases with U bases, or vice versa;
2) deletion or substitution of up to two bases;
3) addition of one base to one or both ends of the sequence; or
4) deletion of one base at one or more ends of the sequence; and
wherein the molecule can bind to a target site to cause exon skipping in an exon of the dystrophin gene.
9. The composition of claim 8 , wherein the antisense oligonucleotide is a morpholino oligomer or a PNA oligomer.
10. The composition of claim 8 , wherein the antisense oligonucleotide comprises a phosphorodiamidate-linked morpholino oligomer.
11. The composition of claim 8 , wherein the polymer is a peptide.